India's Reddy joins the competition of "bulk purchasing", and the generic drug market pattern is reshaped
As an important means for the country to promote the substitution of generic drugs for original research drugs, after the first batch of 25 varieties in the first half of the first half of the year, the pilot batch of 25 varieties were implemented in "4+7" cities, and the National Medical Insurance Bureau quickly implemented nationwide. These 25 varieties are purchased with quantity.
With the in-depth promotion of the 4+7 volume-based procurement model, the 4+7 volume-based procurement follows the principle of "consistent quality, lower price", and promotes the competition between original research drugs and generic drugs, and the price of products will inevitably decline. .
▲ (In the CCTV Finance Channel, Indian medicine was highly affirmed)
Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.
On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.
Official announcement! Seriously, don't be distracted!
On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.
Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.
From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".